Ferrets exclusively synthesize Neu5Ac and express naturally humanized influenza A virus receptors

Mammals express the sialic acids ​N-acetylneuraminic acid (​Neu5Ac) and ​N-glycolylneuraminic acid (​Neu5Gc) on cell surfaces, where they act as receptors for pathogens, including influenza A virus (IAV). ​Neu5Gc is synthesized from ​Neu5Ac by the enzyme cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH). In humans, this enzyme is inactive and only ​Neu5Ac is produced. Ferrets are susceptible to human-adapted IAV strains and have been the dominant animal model for IAV studies. Here we show that ferrets, like humans, do not synthesize ​Neu5Gc. Genomic analysis reveals an ancient, nine-exon deletion in the ferret CMAH gene that is shared by the Pinnipedia and Musteloidia members of the Carnivora. Interactions between two human strains of IAV with the sialyllactose receptor (sialic acid—α2,6Gal) confirm that the type of terminal sialic acid contributes significantly to IAV receptor specificity. Our results indicate that exclusive expression of ​Neu5Ac contributes to the susceptibility of ferrets to human-adapted IAV strains

Investigating the Effects of Homocysteine as an Agonist on Invertebrate Glutamatergic Synapses

Hyperhomocysteinemia (HHcy) in mammals can produce neurological deficits, such as memory loss. The cause of the neurological issues is assumed to be due to homocysteine (HCY) binding to glutamatergic receptors in the central nervous system (CNS). High levels of HCY in the CNS are also associated with Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s disease. Thus, understanding the detailed mechanisms of HCY in model preparations could be useful in developing potential treatments to neurodegenerative diseases with overlapping symptoms to HHcy. The aim of this study is to investigate the efficacy of HCY as an agonist at glutamatergic synapses in invertebrates. The glutamatergic synapses of the larval Drosophila melanogaster (D. melanogaster) and Procambarus clarkii (P. clarkii) neuromuscular junctions (NMJs) were utilized to examine the effects of applying HCY. Measurements of evoked synaptic transmission in both preparations revealed that 100 mM of HCY did not have any consistent effect. The expectation was that the acute action of HCY would have activated the glutamate receptors and then desensitized them so evoked transmission would be blocked. The pharmacological receptor profile of these NMJ receptors are of a quisqualate subtype and not a kainate, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) or N-methyl-D-aspartate receptor (NMDA) subtype. Consequently, HCY may not have any action on quisqualate glutamate receptor subtypes. The findings of this experiments could provide clinical implications regarding relevant pharmacological treatments in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease

Effects of Clove Oil (Eugenol) on Proprioceptive Neurons, Heart Rate, and Behavior in Model Crustaceans

Clove oil contains eugenol as an active ingredient and is used as a topical anesthetic in mammals to remedy pain and to anesthetize fish and other seafood for short periods; however, the exact mechanism of action of eugenol is not fully understood. We examined use of eugenol as a reversible anesthetic in crustaceans by examining its effect on sensory and motor neurons in the Red Swamp crayfish (Procambarus clarkii), Blue crab (Callinectes sapidus) and Whiteleg shrimp (Litopenaeus vannamei) with electrophysiological recordings. The neurogenic heart rate in the three species was also monitored along with behaviors and responsiveness to sensory stimuli. The activity of the primary proprioceptive neurons was reduced at 200 ppm and ceased at 400 ppm for both crayfish (i.e., muscle receptor organ) and crab (i.e., leg PD organ) preparations when exposed to saline containing eugenol. Flushing out eugenol resulted in recovery in the majority of the preparations within five to ten minutes. Administering eugenol to crayfish and crabs both systemically and through environmental exposure resulted in the animals becoming lethargic. Direct injection into the hemolymph was quicker to decrease reflexes and sensory perception, but heart rate was still maintained. Eugenol at a circulating level of 400 ppm decreased electromyogram activity in the claw muscle of crabs. Surprisingly, this study found no change in heart rate despite administering eugenol into the hemolymph to reach 400 ppm in crabs or crayfish but heart rate in shrimp preparations decreased. Our results demonstrate the feasibility of eugenol as a short-term anesthetic for crustaceans to decrease stress during handling or transportation, considering its effectiveness at decreasing sensory input and the quick recovery of upon removal of eugenol. A neurophysiology course took this project on as an authentic course-based undergraduate research experience (ACURE)

EXACT: EXercise or Advice after ankle fraCTure. Design of a randomised controlled trial

<p>Abstract</p> <p>Background</p> <p>Ankle fractures are common. Management of ankle fractures generally involves a period of immobilisation followed by rehabilitation to reduce pain, stiffness, weakness and swelling. The effects of a rehabilitation program are still unclear. However, it has been shown that important components of rehabilitation programs may not confer additional benefits over exercise alone. The primary aim of this trial is to determine the effectiveness and cost-effectiveness of an exercise-based rehabilitation program after ankle fracture, compared to advice alone.</p> <p>Methods/Design</p> <p>A pragmatic randomised trial will be conducted. Participants will be 342 adults with stiff, painful ankles after ankle fracture treated with immobilisation. They will be randomly allocated using a concealed randomisation procedure to either an <it>Advice </it>or <it>Rehabilitation </it>group. Participants in the <it>Advice </it>group will receive verbal and written advice about exercise at the time of removal of immobilisation. Participants in the <it>Rehabilitation </it>group will be provided with a 4-week rehabilitation program that is designed, monitored and progressed by a physiotherapist, in addition to verbal and written advice. Outcomes will be measured by a blinded assessor at 1, 3 and 6 months. The primary outcomes will be activity limitation and quality-adjusted life years.</p> <p>Discussion</p> <p>This pragmatic trial will determine if a rehabilitation program reduces activity limitation and improves quality of life, compared to advice alone, after immobilisation for ankle fracture.</p

Presentation and Outcomes of Infants With Idiopathic Cholestasis: A Multicenter Prospective Study

Objectives: The aim of the study was to determine the frequency and natural history of infantile idiopathic cholestasis (IC) in a large, prospective, multicenter cohort of infants. Methods: We studied 94 cholestatic infants enrolled up to 6 months of age in the NIDDK ChiLDReN (Childhood Liver Disease Research Network) "PROBE" protocol with a final diagnosis of IC; they were followed up to 30 months of age. Results: Male sex (66/94; 70%), preterm birth (22/90 with data; 24% born at 1 mg/dL and/or ALT > 35 U/L; n = 7), and exited healthy (resolved disease per study site report but without documented biochemical resolution; n = 34). Biochemical resolution occurred at median of 9 months of age. GGT was <100 U/L at baseline in 34 of 83 participants (41%). Conclusions: Frequency of IC and of death or liver transplant was less common in this cohort than in previously published cohorts, likely because of recent discovery and diagnosis of genetic etiologies of severe/persistent cholestasis that previously were labeled as idiopathic. Preterm birth and other factors associated with increased vulnerability in neonates are relatively frequent and may contribute to IC. Overall outcome in IC is excellent. Low/normal GGT was common, possibly indicating a role for variants in genes associated with low-GGT cholestasis-this warrants further study

A randomised controlled trial of a patient based Diabetes recall and Management system: the DREAM trial: A study protocol [ISRCTN32042030]

BACKGROUND: Whilst there is broad agreement on what constitutes high quality health care for people with diabetes, there is little consensus on the most efficient way of delivering it. Structured recall systems can improve the quality of care but the systems evaluated to date have been of limited sophistication and the evaluations have been carried out in small numbers of relatively unrepresentative settings. Hartlepool, Easington and Stockton currently operate a computerised diabetes register which has to date produced improvements in the quality of care but performance has now plateaued leaving substantial scope for further improvement. This study will evaluate the effectiveness and efficiency of an area wide 'extended' system incorporating a full structured recall and management system, actively involving patients and including clinical management prompts to primary care clinicians based on locally-adapted evidence based guidelines. METHODS: The study design is a two-armed cluster randomised controlled trial of 61 practices incorporating evaluations of the effectiveness of the system, its economic impact and its impact on patient wellbeing and functioning

Production and hydration of calcium sulfoaluminate-belite cements derived from aluminium anodising sludge

Calcium sulfoaluminate-belite cement (CSAB) offers lower CO2 emissions in its production, compared with Portland cement. However, for the production of CSAB a high amount of alumina is required, and the scarcity and high cost of high-purity bauxite make these cements costly at present. In this study, the use of uncalcined aluminium anodising sludge (AAS) as the main source of alumina to produce CSAB clinkers, replacing bauxite, was assessed. The CSAB clinkers produced were mainly composed of ye’elimite and belite, along with minor traces of alite, and/or brownmillerite, depending on the alumina source. Clinkers derived from AAS as a source of aluminium showed a lower content of ye’elimite (35.5%), as well as the formation of alite (8.2%) when compared to a reference clinker produced with reagent-grade materials. Comparable hydration products were identified in the hydrated cements independent of the alumina source used. The use of AAS to produce CSAB cement was proven to be technically feasible, and the cement thus produced has desirable technical characteristics, presenting high mechanical strength (>40 MPa in paste samples)